Vaccine tourism’? Mumbai travel firm touts US holiday packages with promise of Covid shots  |  Photo Credit: Thinkstock
- For Rs 1.75 lakh, Mumbai-based travel company is offering four-day travel packages with Covid-19 vaccine as the main attraction
- Pfizer-BioNTech have filed for emergency regulatory clearance for their vaccine in US
- First round of vaccines are expected to be given out in America starting December 13
Mumbai: A Mumbai-based travel company is offering what it calls “vaccine tourism” to those who want to be the first in the line to get Covid-19 shots.
The travel firm is trying to lure customers by peddling four-day tour packages worth Rs 1.75 lakhs to the United States in order to get Covid-19 vaccination.
Capitalising on the people’s fear of the pandemic and availability of such doses in India, the travel firm is offering potential takers a chance to “be the first” to get inoculated against the deadly viral pathogen, according to a Times of India report.
A WhatsApp teaser message from the company reads, “As soon as the Pfizer vaccine is officially published to sell in America (tentative date December 11), we are ready to get done for a select few clients”.
The cost of Rs 1.75 lakh includes Delhi-New York-Delhi air ticket return fare, hotel tariff for three days and four nights and a vaccine shot.
“We are not holding or procuring any vaccine. Everything we will arrange will be within laws of the US. We will only process your requirements. Right now, no time frame can be committed. We do not collect any advance or deposits now. We just need your registration with us with your name, email address, phone number, age, and one of your physical complications and passport copy. Rest everything will be done as per official permissions of the health department there. Unless they allow official sales to people other than Americans, we cannot give you the vaccine,” the message reads.
The first rounds of vaccinations are expected to be given to select Americans starting December 13, as per reports in US media.
The American pharma company Moderna claimed that its vaccine is 94.5% effective on COVID patients, and shortly after another US drugmaker Pfizer along with its German collaborator BioNTech applied for emergency regulatory clearance in the US.
BioNTech SE Chief Executive Ugur Sahin earlier said that the US Food and Drug Administration may grant emergency-use approval by mid-December while approval in the European Union may be secured by the tail end of December.